Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 455

1.

Synthesis of Functionalized Cannabilactones.

Liu Y, Ho TC, Baradwan M, Pascual Lopez-Alberca M, Iliopoulos-Tsoutsouvas C, Nikas SP, Makriyannis A.

Molecules. 2020 Feb 6;25(3). pii: E684. doi: 10.3390/molecules25030684.

2.

Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures.

Hua T, Li X, Wu L, Iliopoulos-Tsoutsouvas C, Wang Y, Wu M, Shen L, Johnston CA, Nikas SP, Song F, Song X, Yuan S, Sun Q, Wu Y, Jiang S, Grim TW, Benchama O, Stahl EL, Zvonok N, Zhao S, Bohn LM, Makriyannis A, Liu ZJ.

Cell. 2020 Feb 20;180(4):655-665.e18. doi: 10.1016/j.cell.2020.01.008. Epub 2020 Jan 30.

PMID:
32004463
3.

Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors.

Malamas MS, Farah SI, Lamani M, Pelekoudas DN, Perry NT, Rajarshi G, Miyabe CY, Chandrashekhar H, West J, Pavlopoulos S, Makriyannis A.

Bioorg Med Chem. 2020 Jan 1;28(1):115195. doi: 10.1016/j.bmc.2019.115195. Epub 2019 Nov 11.

PMID:
31761726
4.

A new antibiotic selectively kills Gram-negative pathogens.

Imai Y, Meyer KJ, Iinishi A, Favre-Godal Q, Green R, Manuse S, Caboni M, Mori M, Niles S, Ghiglieri M, Honrao C, Ma X, Guo JJ, Makriyannis A, Linares-Otoya L, Böhringer N, Wuisan ZG, Kaur H, Wu R, Mateus A, Typas A, Savitski MM, Espinoza JL, O'Rourke A, Nelson KE, Hiller S, Noinaj N, Schäberle TF, D'Onofrio A, Lewis K.

Nature. 2019 Dec;576(7787):459-464. doi: 10.1038/s41586-019-1791-1. Epub 2019 Nov 20.

PMID:
31747680
5.

Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.

Kangas BD, Zakarian AS, Vemuri K, Alapafuja SO, Jiang S, Nikas SP, Makriyannis A, Bergman J.

J Pharmacol Exp Ther. 2020 Jan;372(1):119-127. doi: 10.1124/jpet.119.261818. Epub 2019 Oct 22.

PMID:
31641018
6.

Piperidine and piperazine inhibitors of fatty acid amide hydrolase targeting excitotoxic pathology.

Lamani M, Malamas MS, Farah SI, Shukla VG, Almeida MF, Weerts CM, Anderson J, Wood JT, Farizatto KLG, Bahr BA, Makriyannis A.

Bioorg Med Chem. 2019 Dec 1;27(23):115096. doi: 10.1016/j.bmc.2019.115096. Epub 2019 Sep 10.

PMID:
31629610
7.

Chain Substituted Cannabilactones with Selectivity for the CB2 Cannabinoid Receptor.

Alapafuja SO, Nikas SP, Ho TC, Tong F, Benchama O, Makriyannis A.

Molecules. 2019 Oct 1;24(19). pii: E3559. doi: 10.3390/molecules24193559.

8.

Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43].

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2019 Nov 5;862:172656. doi: 10.1016/j.ejphar.2019.172656. Epub 2019 Sep 10. No abstract available.

PMID:
31519354
9.

Probing the CB1 Cannabinoid Receptor Binding Pocket with AM6538, a High-Affinity Irreversible Antagonist.

Laprairie RB, Vemuri K, Stahl EL, Korde A, Ho JH, Grim TW, Hua T, Wu Y, Stevens RC, Liu ZJ, Makriyannis A, Bohn LM.

Mol Pharmacol. 2019 Nov;96(5):619-628. doi: 10.1124/mol.119.116483. Epub 2019 Sep 12.

PMID:
31515283
10.

In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors.

Sachdev S, Vemuri K, Banister SD, Longworth M, Kassiou M, Santiago M, Makriyannis A, Connor M.

Br J Pharmacol. 2019 Dec;176(24):4653-4665. doi: 10.1111/bph.14829. Epub 2019 Dec 10.

PMID:
31412133
11.

The novel cannabinoid CB1 receptor agonist AM11101 increases food intake in female rats.

Ogden SB, Malamas MS, Makriyannis A, Eckel LA.

Br J Pharmacol. 2019 Oct;176(20):3972-3982. doi: 10.1111/bph.14797. Epub 2019 Sep 6.

PMID:
31328790
12.

Cannabinoid CB1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity.

Argueta DA, Perez PA, Makriyannis A, DiPatrizio NV.

Front Physiol. 2019 Jun 11;10:704. doi: 10.3389/fphys.2019.00704. eCollection 2019.

13.

The sesquiterpene beta-caryophyllene oxide attenuates ethanol drinking and place conditioning in mice.

Oppong-Damoah A, Blough BE, Makriyannis A, Murnane KS.

Heliyon. 2019 Jun 12;5(6):e01915. doi: 10.1016/j.heliyon.2019.e01915. eCollection 2019 Jun.

14.

Endocannabinoid Metabolome Characterization of Milk from Guatemalan Women Living in the Western Highlands.

Gaitán AV, Wood JT, Solomons NW, Donohue JA, Ji L, Liu Y, Nikas SP, Zhang F, Allen LH, Makriyannis A, Lammi-Keefe CJ.

Curr Dev Nutr. 2019 Mar 27;3(6):nzz018. doi: 10.1093/cdn/nzz018. eCollection 2019 Jun.

15.

Chronic low dose arsenic exposure preferentially perturbs mitotic phase of the cell cycle.

Ganapathy S, Liu J, Xiong R, Yu T, Makriyannis A, Chen C.

Genes Cancer. 2019 Feb;10(1-2):39-51. doi: 10.18632/genesandcancer.185.

16.

Biochemical and Proteomic Characterization of Recombinant Human α/β Hydrolase Domain 6.

Shields CM, Zvonok N, Zvonok A, Makriyannis A.

Sci Rep. 2019 Jan 29;9(1):890. doi: 10.1038/s41598-018-36633-4.

17.

Crystal Structure of the Human Cannabinoid Receptor CB2.

Li X, Hua T, Vemuri K, Ho JH, Wu Y, Wu L, Popov P, Benchama O, Zvonok N, Locke K, Qu L, Han GW, Iyer MR, Cinar R, Coffey NJ, Wang J, Wu M, Katritch V, Zhao S, Kunos G, Bohn LM, Makriyannis A, Stevens RC, Liu ZJ.

Cell. 2019 Jan 24;176(3):459-467.e13. doi: 10.1016/j.cell.2018.12.011. Epub 2019 Jan 10.

18.

Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.

D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD.

Lancet Psychiatry. 2019 Jan;6(1):35-45. doi: 10.1016/S2215-0366(18)30427-9. Epub 2018 Dec 6.

PMID:
30528676
19.

Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.

Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG.

Mol Pharmacol. 2019 Feb;95(2):155-168. doi: 10.1124/mol.118.113233. Epub 2018 Nov 30.

20.

Cannabinoid-induced lower lip retraction in rats.

Chopda GR, Nikas SP, Sharma R, Kulkarni S, Makriyannis A, Paronis CA.

Psychopharmacology (Berl). 2019 Apr;236(4):1199-1206. doi: 10.1007/s00213-018-5125-z. Epub 2018 Nov 20.

PMID:
30460515
21.

Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment.

Alapafuja SO, Malamas MS, Shukla V, Zvonok A, Miller S, Daily L, Rajarshi G, Miyabe CY, Chandrashekhar H, Wood J, Tyukhtenko S, Straiker A, Makriyannis A.

Bioorg Med Chem. 2019 Jan 1;27(1):55-64. doi: 10.1016/j.bmc.2018.11.003. Epub 2018 Nov 3.

PMID:
30446439
22.

Aliphatic Azides as Selective Cysteine Labeling Reagents for Integral Membrane Proteins.

Szymanski D, Papanastasiou M, Pandarinathan L, Zvonok N, Janero DR, Pavlopoulos S, Vouros P, Makriyannis A.

J Med Chem. 2018 Dec 27;61(24):11199-11208. doi: 10.1021/acs.jmedchem.8b01302. Epub 2018 Dec 10.

PMID:
30444608
23.

Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward.

Sagheddu C, Scherma M, Congiu M, Fadda P, Carta G, Banni S, Wood JT, Makriyannis A, Malamas MS, Pistis M.

Neuropharmacology. 2019 Jan;144:327-336. doi: 10.1016/j.neuropharm.2018.11.013. Epub 2018 Nov 12.

PMID:
30439418
24.
25.

Fluorescent probes for G-protein-coupled receptor drug discovery.

Iliopoulos-Tsoutsouvas C, Kulkarni RN, Makriyannis A, Nikas SP.

Expert Opin Drug Discov. 2018 Oct;13(10):933-947. doi: 10.1080/17460441.2018.1518975. Epub 2018 Sep 24. Review.

PMID:
30249143
26.

Endocannabinoid Metabolome Characterization of Transitional and Mature Human Milk.

Gaitán AV, Wood JT, Zhang F, Makriyannis A, Lammi-Keefe CJ.

Nutrients. 2018 Sep 12;10(9). pii: E1294. doi: 10.3390/nu10091294.

27.

( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.

Liu Y, Ji L, Eno M, Kudalkar S, Li AL, Schimpgen M, Benchama O, Morales P, Xu S, Hurst D, Wu S, Mohammad KA, Wood JT, Zvonok N, Papahatjis DP, Zhou H, Honrao C, Mackie K, Reggio P, Hohmann AG, Marnett LJ, Makriyannis A, Nikas SP.

J Med Chem. 2018 Oct 11;61(19):8639-8657. doi: 10.1021/acs.jmedchem.8b00611. Epub 2018 Sep 21.

PMID:
30196704
28.

Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy.

Barutta F, Bellini S, Mastrocola R, Gambino R, Piscitelli F, di Marzo V, Corbetta B, Vemuri VK, Makriyannis A, Annaratone L, Bruno G, Gruden G.

Br J Pharmacol. 2018 Dec;175(23):4371-4385. doi: 10.1111/bph.14495. Epub 2018 Nov 6.

29.

Oximes short-acting CB1 receptor agonists.

Malamas MS, Raghav JG, Ma X, Honrao C, Wood JT, Benchama O, Zhou H, Mallipeddi S, Makriyannis A.

Bioorg Med Chem. 2018 Oct 1;26(18):4963-4970. doi: 10.1016/j.bmc.2018.08.003. Epub 2018 Aug 2.

PMID:
30122284
30.

The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2018 Oct 5;836:34-43. doi: 10.1016/j.ejphar.2018.08.016. Epub 2018 Aug 17. Erratum in: Eur J Pharmacol. 2019 Nov 5;862:172656.

PMID:
30121173
31.

Endocannabinoid regulation of homeostatic feeding and stress-induced alterations in food intake in male rats.

Sticht MA, Lau DJ, Keenan CM, Cavin JB, Morena M, Vemuri VK, Makriyannis A, Cravatt BF, Sharkey KA, Hill MN.

Br J Pharmacol. 2019 May;176(10):1524-1540. doi: 10.1111/bph.14453. Epub 2018 Aug 22.

PMID:
30051485
32.

Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats.

He XH, Jordan CJ, Vemuri K, Bi GH, Zhan J, Gardner EL, Makriyannis A, Wang YL, Xi ZX.

Acta Pharmacol Sin. 2019 Mar;40(3):365-373. doi: 10.1038/s41401-018-0059-x. Epub 2018 Jul 2.

33.

Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure.

Miller S, Kulkarni S, Ciesielski A, Nikas SP, Mackie K, Makriyannis A, Straiker A.

Pharmaceuticals (Basel). 2018 May 22;11(2). pii: E50. doi: 10.3390/ph11020050.

34.

Hydrogen-Deuterium Exchange Mass Spectrometry to Study Protein Complexes.

Kochert BA, Iacob RE, Wales TE, Makriyannis A, Engen JR.

Methods Mol Biol. 2018;1764:153-171. doi: 10.1007/978-1-4939-7759-8_10.

PMID:
29605914
35.

A lethal synergy induced by phellinus linteus and camptothecin11 in colon cancer cells.

Yu T, Ganapathy S, Shen L, Peng B, Kim SH, Makriyannis A, Chen C.

Oncotarget. 2018 Jan 4;9(5):6308-6319. doi: 10.18632/oncotarget.23918. eCollection 2018 Jan 19.

36.

Expression, Purification and Characterization of the Human Cannabinoid 1 Receptor.

Mallipeddi S, Zvonok N, Makriyannis A.

Sci Rep. 2018 Feb 13;8(1):2935. doi: 10.1038/s41598-018-19749-5.

37.

Effects of Distal Mutations on the Structure, Dynamics and Catalysis of Human Monoacylglycerol Lipase.

Tyukhtenko S, Rajarshi G, Karageorgos I, Zvonok N, Gallagher ES, Huang H, Vemuri K, Hudgens JW, Ma X, Nasr ML, Pavlopoulos S, Makriyannis A.

Sci Rep. 2018 Jan 29;8(1):1719. doi: 10.1038/s41598-017-19135-7.

38.

Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.

Paronis CA, Chopda GR, Vemuri K, Zakarian AS, Makriyannis A, Bergman J.

J Pharmacol Exp Ther. 2018 Mar;364(3):485-493. doi: 10.1124/jpet.117.245647. Epub 2018 Jan 8.

39.

Secretion, isotopic labeling and deglycosylation of N-acylethanolamine acid amidase for biophysical studies.

Pavlopoulos S, Pelekoudas DN, Benchama O, Rawlins CM, Agar JN, West JM, Malamas M, Zvonok N, Makriyannis A.

Protein Expr Purif. 2018 May;145:108-117. doi: 10.1016/j.pep.2017.12.005. Epub 2017 Dec 15.

40.

Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling.

Balla A, Dong B, Shilpa BM, Vemuri K, Makriyannis A, Pandey SC, Sershen H, Suckow RF, Vinod KY.

Neuropharmacology. 2018 Mar 15;131:200-208. doi: 10.1016/j.neuropharm.2017.10.040. Epub 2017 Nov 3.

41.

Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages.

Ruiz de Azua I, Mancini G, Srivastava RK, Rey AA, Cardinal P, Tedesco L, Zingaretti CM, Sassmann A, Quarta C, Schwitter C, Conrad A, Wettschureck N, Vemuri VK, Makriyannis A, Hartwig J, Mendez-Lago M, Bindila L, Monory K, Giordano A, Cinti S, Marsicano G, Offermanns S, Nisoli E, Pagotto U, Cota D, Lutz B.

J Clin Invest. 2017 Nov 1;127(11):4148-4162. doi: 10.1172/JCI83626. Epub 2017 Oct 16.

42.

Cannabinoid CB1 Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors.

Leonard MZ, Alapafuja SO, Ji L, Shukla VG, Liu Y, Nikas SP, Makriyannis A, Bergman J, Kangas BD.

J Pharmacol Exp Ther. 2017 Dec;363(3):314-323. doi: 10.1124/jpet.117.244392. Epub 2017 Sep 25.

43.

The role of human monoacylglycerol lipase (hMAGL) binding pocket in breakup of unsaturated phospholipid membranes.

Karageorgos I, Silin VI, Zvonok N, Marino J, Janero DR, Makriyannis A.

Anal Biochem. 2017 Nov 1;536:90-95. doi: 10.1016/j.ab.2017.08.009. Epub 2017 Aug 17.

PMID:
28822686
44.

Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

Farizatto KLG, McEwan SA, Naidoo V, Nikas SP, Shukla VG, Almeida MF, Byrd A, Romine H, Karanian DA, Makriyannis A, Bahr BA.

J Mol Neurosci. 2017 Sep;63(1):115-122. doi: 10.1007/s12031-017-0963-4. Epub 2017 Aug 12.

PMID:
28803438
45.

Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.

Janero DR, Korde A, Makriyannis A.

Methods Enzymol. 2017;593:217-235. doi: 10.1016/bs.mie.2017.06.022. Epub 2017 Jul 3.

PMID:
28750804
46.

CB₁ receptor antagonism in the bed nucleus of the stria terminalis interferes with affective opioid withdrawal in rats.

Wills KL, DeVuono MV, Limebeer CL, Vemuri K, Makriyannis A, Parker LA.

Behav Neurosci. 2017 Aug;131(4):304-11. doi: 10.1037/bne0000201.

PMID:
28714716
47.

Crystal structures of agonist-bound human cannabinoid receptor CB1.

Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, Pu M, Korde A, Jiang S, Ho JH, Han GW, Ding K, Li X, Liu H, Hanson MA, Zhao S, Bohn LM, Makriyannis A, Stevens RC, Liu ZJ.

Nature. 2017 Jul 27;547(7664):468-471. doi: 10.1038/nature23272. Epub 2017 Jul 5.

48.

C1'-Azacycloalkyl Hexahydrocannabinols.

Ho TC, Shimada N, Tius MA, Nikas SP, Zhang W, Makriyannis A.

J Org Chem. 2017 Aug 4;82(15):7839-7849. doi: 10.1021/acs.joc.7b00988. Epub 2017 Jul 17.

PMID:
28677397
49.

s signalling of the CB1 receptor and the influence of receptor number.

Finlay DB, Cawston EE, Grimsey NL, Hunter MR, Korde A, Vemuri VK, Makriyannis A, Glass M.

Br J Pharmacol. 2017 Aug;174(15):2545-2562. doi: 10.1111/bph.13866. Epub 2017 Jun 19.

50.

Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells.

Ganapathy S, Peng B, Shen L, Yu T, Lafontant J, Li P, Xiong R, Makriyannis A, Chen C.

Oncotarget. 2017 May 9;8(19):30992-31002. doi: 10.18632/oncotarget.16047.

Supplemental Content

Loading ...
Support Center